Back to search

Article

RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia

2024-01-25

Abstract excerpt

<title>Abstract</title><p>There is a growing body of investigation currently underway on MDM2 inhibitors in clinical trials, reflecting the increasing interest in including these drugs in cancer treatment regimens. One of the developed compounds, idasanutlin (RG7388), has shown promise in early-stage clinical trials. It is a second-generation MDM2-p53 binding antagonist with enhanced potency, selectivity, and bioa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
371b4515-eb72-5dca-b37b-9db6cb4d69b8
DOI
10.21203/rs.3.rs-3887898/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaDOI 10.21203/rs.3.rs-3887898/v1
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia.Semantic proximity
Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Semantic proximity
Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity
The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.Semantic proximity
A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity
Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome LevelSemantic proximity
A Novel Approach to Classifying Chemotherapeutic Agents Based on Their Impact on Canonical Pathways: Implications for Overcoming Multidrug Resistance in Breast CancerSemantic proximity
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 InhibitionSemantic proximity
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia modelsSemantic proximity
Integrative Multi-Omics Analysis Unveils the Molecular Mechanisms by Which TP53 Mutation Influence Early Decitabine Resistance in Myelodysplastic Syndrome.Semantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity
Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia CellsSemantic proximity
Select a neighboring publication to make it the new centre.